MedTrace Logo

Hip Fracture Study of GSK576428 (Fondaparinux Sodium)

NCT00320424 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2018-09-04

Study results available
· View outcomes & findings →

Summary

This study is requested by PMDA to confirm the efficacy and the safety for HFS.

Conditions

  • Thromboembolism

Interventions

DRUG

Fondaparinux

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-16
Primary Completion
2006-10-26
Completion
2006-10-26

Countries

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00320424 on ClinicalTrials.gov